{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:03:35Z","timestamp":1782601415852,"version":"3.54.5"},"reference-count":18,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004752","name":"Victorian State Government","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001215","name":"La Trobe University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001215","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["#1055456"],"award-info":[{"award-number":["#1055456"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1111\/jcpt.12366","type":"journal-article","created":{"date-parts":[[2016,2,28]],"date-time":"2016-02-28T07:37:07Z","timestamp":1456645027000},"page":"354-356","source":"Crossref","is-referenced-by-count":4,"title":["Non-HIV-associated Kaposi sarcoma in an immunosuppressed melanoma patient treated with dabrafenib"],"prefix":"10.1155","volume":"41","author":[{"given":"S.","family":"Parakh","sequence":"first","affiliation":[{"name":"Medical Oncology Unit; Austin Health; Heidelberg Vic. Australia"},{"name":"Olivia Newton-John Cancer Research Institute; Heidelberg Vic. Australia"},{"name":"School of Cancer Medicine; La Trobe University; Vic. Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Goh","sequence":"additional","affiliation":[{"name":"Dermatology Unit; Austin Health; Heidelberg Vic. Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Andrews","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit; Austin Health; Heidelberg Vic. Australia"},{"name":"Olivia Newton-John Cancer Research Institute; Heidelberg Vic. Australia"},{"name":"Department of Medicine; University of Melbourne; Parkville Vic. Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,2,28]]},"reference":[{"key":"10.1111\/jcpt.12366-BIB0001|jcpt12366-cit-0001","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1111\/jcpt.12366-BIB0002|jcpt12366-cit-0002","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12366-BIB0003|jcpt12366-cit-0003","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12366-BIB0004|jcpt12366-cit-0004","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12366-BIB0005|jcpt12366-cit-0005","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.critrevonc.2013.06.002","article-title":"Cutaneous toxicities of BRAF inhibitors: clinical and pathological challenges and call to action","volume":"88","author":"Mandal\u00e0","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1111\/jcpt.12366-BIB0006|jcpt12366-cit-0006","first-page":"13","article-title":"Management of Kaposi sarcoma in resource-limited settings in the era of HAART","volume":"7","author":"Lynen","year":"2005","journal-title":"AIDS Rev"},{"key":"10.1111\/jcpt.12366-BIB0007|jcpt12366-cit-0007","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00005792-199307000-00004","article-title":"Kaposi sarcoma","volume":"72","author":"Martin","year":"1993","journal-title":"Medicine"},{"key":"10.1111\/jcpt.12366-BIB0008|jcpt12366-cit-0008","first-page":"727","article-title":"AIDS-related Kaposi sarcoma: evidence for direct stimulatory effect of glucocorticoid on cell proliferation","volume":"146","author":"Guo","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1111\/jcpt.12366-BIB0009|jcpt12366-cit-0009","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/00007890-199903150-00002","article-title":"Hydrocortisone activation of human herpesvirus 8 viral DNA replication and gene expression in vitro","volume":"67","author":"Hudnall","year":"1999","journal-title":"Transplantation"},{"key":"10.1111\/jcpt.12366-BIB0010|jcpt12366-cit-0010","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/1097-0142(19930901)72:5<1779::AID-CNCR2820720543>3.0.CO;2-M","article-title":"The appearance of Kaposi sarcoma during corticosteroid therapy","volume":"72","author":"Trattner","year":"1993","journal-title":"Cancer"},{"key":"10.1111\/jcpt.12366-BIB0011|jcpt12366-cit-0011","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1099\/vir.0.81628-0","article-title":"Raf\/MEK\/ERK signalling triggers reactivation of Kaposi sarcoma-associated herpesvirus latency","volume":"87","author":"Ford","year":"2006","journal-title":"J Gen Virol"},{"key":"10.1111\/jcpt.12366-BIB0012|jcpt12366-cit-0012","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1128\/JVI.77.2.1524-1539.2003","article-title":"Kaposi sarcoma-associated herpesvirus induces the phosphatidylinositol 3-kinase-PKC-\u03b6-MEK-ERK signaling pathway in target cells early during infection: implications for infectivity","volume":"77","author":"Naranatt","year":"2003","journal-title":"J Virol"},{"key":"10.1111\/jcpt.12366-BIB0013|jcpt12366-cit-0013","unstructured":"Depeille P Young JJ Boguslawski E Duesbery NS MEK\/MAPK signaling in growth and vascularization of Kaposi sarcoma"},{"key":"10.1111\/jcpt.12366-BIB0014|jcpt12366-cit-0014","doi-asserted-by":"crossref","unstructured":"Uldrick TS Wyvill K Peer C et al Phase I and pharmacokinetic study of sorafenib in Kaposi sarcoma 2013","DOI":"10.1200\/jco.2013.31.15_suppl.10588"},{"key":"10.1111\/jcpt.12366-BIB0015|jcpt12366-cit-0015","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1200\/JCO.2013.50.4118","article-title":"BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1\/2 inhibition","volume":"31","author":"Andrews","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12366-BIB0016|jcpt12366-cit-0016","first-page":"412","article-title":"Oral medicine case book 22: case book","volume":"64","author":"De Waal","year":"2009","journal-title":"SADJ"},{"key":"10.1111\/jcpt.12366-BIB0017|jcpt12366-cit-0017","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaad.2008.05.001","article-title":"Kaposi sarcoma: a continuing conundrum","volume":"59","author":"Schwartz","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/jcpt.12366-BIB0018|jcpt12366-cit-0018","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1158\/1055-9965.EPI-08-0671","article-title":"Risk factors for classical Kaposi sarcoma in a population-based case-control study in Sicily","volume":"17","author":"Anderson","year":"2008","journal-title":"Cancer Epidemiol Biomark Prev"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12366","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12366","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12366\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:01:32Z","timestamp":1671818492000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,28]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12366","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2,28]]}}}